Genmab A/S (OTCMKTS:GNMSF) Short Interest Down 23.5% in February

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a decline of 23.5% from the February 13th total of 79,900 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is currently 203.7 days. Currently, 0.1% of the shares of the stock are short sold.

Genmab A/S Stock Performance

Shares of OTCMKTS:GNMSF traded down $3.92 during trading on Tuesday, hitting $204.98. The company’s stock had a trading volume of 4 shares, compared to its average volume of 3,102. The stock’s 50-day moving average price is $210.96 and its two-hundred day moving average price is $222.38. Genmab A/S has a fifty-two week low of $186.61 and a fifty-two week high of $310.56. The company has a market capitalization of $13.54 billion, a PE ratio of 11.70 and a beta of 1.08.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.